Share This
Create Your Own Business Intelligence Website
 
Input the stock code or the company name     Search  

<02186.HK> - LUYE PHARMA GROUP LIMITED

 
 
 Basic Datum
Company name Lot P/E P/B EPS DPS
LUYE PHARMA 500 23.81 0.7339 0.1566 0.0
Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend
 
 
 
 Company Rating
Date Broker Company name Rating Target
04-01   LUYE PHARMA 買入
≫More
 
 Company performance - Published
Date Company name Turnover* Profit* % Dividend
≫More
 
 Comment
2020-06-18 綠葉製藥(2186)昨日大升8%,但股價仍然處低位。綠葉近年受到政府集採政策影響,過去兩年都持續向下。麥格里預計,綠葉製藥可望在2023至24年推出新藥,總收益可達到35億元人民幣,而集團2019年全年收入才65億元。綠葉製藥預測市盈率只有9倍,以藥股來說是非常低殘,反映市場對集團全無預期。一旦新藥成為賣點,在盈利和估值雙雙擴張下,重估空間相當大。
 
2020-06-26 綠葉製藥(2186)專注腫瘤藥、中樞神經治療領域,也涉足心血管、消化與代謝藥物,業務覆蓋中國、美國、歐洲及日本等國家;截至去年底在中國擁有42種處於不同開發階段的在研產品,在美國、歐洲和日本亦擁有15種在研產品。綠葉製藥在今年2月完成收購山東博安,有進軍利生物藥領域。
 
 
 Top Gain / Loss Show All Charts 
 
 Value
Name Updated Value Change Change %
HSI 04-15 09:30 16574.9  146.79  0.88%
LUYE PHARMA 04-16 16:08 2.6  2.6  ∞%
≫More
 
 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.